30 In summary, ABCD Platform - based glaucoma “duet” is designed to address 4 key attributes needed in a next - generation glaucoma therapy Redu ces IOP Durable Safe Neuroprotective • Glaucoma is an optic neuropathy driven by neuroinflammation • The NLRP3 inhibitor targets the NLRP3 inflammasome complex that drives neuroinflammation causing optic neuropathy • The IOP lowering agent addresses the IOP elevation stressor • The NLRP3 inhibitor demonstrates the potential to provide additional IOP reduction effects • The ABCD Platform has a high molecular weight to increase its ocular half - life , providing potential for a quarterly dosed intravitreal therapy • Tarcocimab, an ABC Platform - derived biologic, demonstrated a strong durability profile across multiple pivotal studies • Tarcocimab and the ABCD Platform have demonstrated a favorable safety profile across multiple pivotal studies (>13,000 intravitreal injections) Design attributes of the ABCD Platform - based glaucoma “duet” + + +